• Nie Znaleziono Wyników

The Voice of the Editor-in-Chief


Academic year: 2022

Share "The Voice of the Editor-in-Chief"

Pokaż więcej ( Stron)

Pełen tekst



The Voice of the Editor-in-Chief

Another year has passed since the first issue of

“Clinical Diabetology” published entirely in English was released. It was another year of intense work of the Editorial Board. Specifically, efforts were made to select from the submitted manuscripts those that are believed to be the most interesting and most valuable in terms of their scientific value and potential to be implemented in everyday clinical practice. I would like to thank you all for submitting the manuscripts and active participation in creating and improving our journal. It is important and worth emphasizing that the number of original papers received from foreign authors is constantly increasing, which not only significantly broadens our perspective on broadly- -defined diabetes care in various countries but also improves the rank of “Clinical Diabetology”. Therefore we have decided that the journal will be submitted for evaluation for coverage in other databases: first

the Emerging Sources Citation Index (ESCI), a part of the Web of Science Core Collection, and then in PubMed Central. As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM principles indicating levels of evidence underlying the recommendations has been introduced in most chapters of the 2018 PTD Guidelines (which have been published annually since 2005). In addition, the most important references supporting the recommendations are listed at the end of respective chapters.

With the second issue of “Clinical Diabetology”

this year, I would like to emphasize once again that it is thanks to you that the journal has its current form and shape. I look forward to further fruitful cooperation with you in creating the journal of ever higher scientific quality and practical value. Have a nice reading.


Prof. Janusz Gumprecht

Dear Colleagues,



Powiązane dokumenty

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with

Evidence Based Medicine (EBM) od lat „gości” praktycznie we wszystkich aspektach praktyki lekarskiej i funkcjonuje niemal w całej służbie zdrowia. Prawidłowe jej stosowanie

Analiza zależności między parami zmiennych przyjęła postać tabelaryczną, gdzie dla każ- dej pary wyznaczono kierunek wspólnego oddziaływania danych dwóch czynników na

Ocena związku poszczególnych pozycji podskali IV („Częstości wykorzystywania poszczególnych elementów Evidence-based Practice w codziennej pracy klinicznej”) z ogólnym

Professor Janusz Gumprecht has excellently developed the journal — it appears regularly, contains more and more papers from outside Poland, is included in the Web of Science

Just before the publication of this issue of “Cli- nical Diabetology”, the largest diabetes meeting in the world — 79 th Scientific Sessions of the American Diabetes

Although more than 3,500 years have passed since the first description of the symptoms of diabetes in the Egyptian papyrus dated to around 1550 BC, diabetes is still

differences in the frequency, causes and duration of hospitalization of children with diabetes in different regions of Poland, which implies the need to ensure uniform access

Another challenge is effective and safe use of antidiabetic drugs to minimize side effects, improve adherence, increase the acceptance of the disease and reduce the risk

At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who,

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic

Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that

In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with

In addition to attending the scientific meetings, I also encourage you to read the latest issue of the “Clinical Diabetology”, where, among a number of interesting articles, I would

Considering the above, I would like to draw your attention to two of many interesting articles published in the last issue of Clinical Diabetology: the paper presenting

In accordance with other diabetic organizations (the American Diabetes Association — ADA, the National Institute for Health and Care Excellence — NICE), glycaemic goals has

Here, it should be mentioned that also the LEADER trial, that assessed cardiovascular safety of one of GLP-1 agonists, liraglutide, in the population of type 2 diabetes

Despite recent advances in medicine, introduction of new hypoglycaemic drugs and the fact that more than 3.500 years have passed since the earliest known record of diabetes

The conference brought together a group of distinguished lecturers and almost 500 participants — physicians dealing in their everyday practice with carbohydrate

At the same time, we intend to continue the educational function of the journal and we do not want to hinder the access to its content for the readers; therefore, we decided

This change is a result of systematic de- velopment of our journal aiming at further increasing its presence and importance on the international arena and striving to